Nagendra Natarajan is an Oncology physician affiliated with Nebraska Cancer Specialists. OpenAlex indexes 16 publications with 312 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7500 Mercy Rd Ste 1300
Omaha, NE 681242319
Telephone
402-334-4773Provider last certified this registry record 1 Oct 2025.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20252 payments
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- Boehringer Ingelheim International GmbHProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
38.8%Iron, parenteral preparations27.7%Ferric carboxymaltose100%Part B, office-administered≥16 patientsErythropoiesis-stimulating Agent10.8%Darbepoetin alfa100%Part B, office-administered≥11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
24.2%Other antiemetics20.1%Fosaprepitant100%Part B, office-administered≥24 patientsSerotonin-3 Receptor Antagonist3.2%Palonosetron hcl54%Ondansetron hydrochloride42%Ondansetron Hcl4%Part D + Part B≥58 patients+ 4 more classes in this area
Cancer & immunology
19.7%PD-1 inhibitor17.5%Pembrolizumab100%Part B, office-administered≥14 patientsNucleoside Metabolic Inhibitor1.1%Fluorouracil100%Part B, office-administered≥13 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Postoperative critical care and high-acuity care provision in the United Kingdom, Australia, and New Zealand
British Journal of Anaesthesia
2019 - Improving care at scale: Process evaluation of a multi-component quality improvement intervention to reduce mortality after emergency abdominal surgery (EPOCH trial)
Implementation Science
2018
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”